Search
Bicara Therapeutics Inc
BCAXAdd to Watchlist
27.100USD
+0.830+3.16%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.78BMarket Cap
LossP/E TTM
More Details of Bicara Therapeutics Inc Company
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Bicara Therapeutics Inc Info
Ticker SymbolBCAX
Company nameBicara Therapeutics Inc
IPO dateSep 13, 2024
CEOMazumdar (Claire)
Number of employees55
Security typeOrdinary Share
Fiscal year-endSep 13
Address116 Huntington Avenue Suite 703
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16174684219
Websitehttps://www.bicara.com/
Ticker SymbolBCAX
IPO dateSep 13, 2024
CEOMazumdar (Claire)
Company Executives of Bicara Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
362.15K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
181.64K
-5.51%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
129.84K
-11.94%
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Vijay Kuchroo, Ph.D.
Dr. Vijay Kuchroo, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Director
Independent Director
--
--
Mr. Scott Robertson
Mr. Scott Robertson
Independent Director
Independent Director
--
--
Ms. Lara S. Meisner, J.D.
Ms. Lara S. Meisner, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Dr. Carolyn Ng, Ph.D.
Dr. Carolyn Ng, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
362.15K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
181.64K
-5.51%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
129.84K
-11.94%
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Vijay Kuchroo, Ph.D.
Dr. Vijay Kuchroo, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of Bicara Therapeutics Inc?
The top five shareholders of Bicara Therapeutics Inc are: Dr. Claire Mazumdar, Ph.D.
How many institutions hold shares of Bicara Therapeutics Inc (BCAX)?
As of 2026Q1, 287 institutions hold shares of Bicara Therapeutics Inc, with a combined market value of approximately 61.73M, accounting for 94.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4151635.00.